metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus paclitaxel
	avelumab alone vs. paclitaxel	1			-
	pembrolizumab alone vs. paclitaxel	1			-
versus placebo
	nivolumab alone vs. placebo	1			-
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
versus paclitaxel
	pembrolizumab alone vs. paclitaxel	1			-